Methods of treating cancer using PD-1 axis binding antagonists and tigit inhibitors
US10611836B2 · kind B2 · utility
2Cited by
16References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 17, 2016 |
| Grant date | Apr 7, 2020 |
| Priority date | — |
| Expiry date | Nov 16, 2037 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.